In vitro activity of itraconazole against yeast and mycelial fungi – pathogens of opportunistic mycoses in tuberculosis patients
https://doi.org/10.54921/2413-0346-2024-12-4-18-24
Abstract
The aim of the study was to determine the levels of sensitivity to itraconazole in 51 species of opportunistic fungi isolated from tuberculosis patients in the diagnosis of bronchopulmonary and disseminated mycoses.
Materials and methods. The sensitivity levels to itraconazole of 902 clinical strains of yeast fungi from the genera Candida (14 species), Cryptococcus (3 species), Geotrichum (1 species) were determined, Hanseniaspora (1 species), Saccharomyces (1 species), Saprochaete (1 species), Rhodotorula (2 species), Trichosporon (1 species) and mycelial fungi from the genera Acremonium (1 species), Alternaria (1 species), Aspergillus (12 species), Aureobasidium (1 species), Cladosporium (1 species), Curvularia (1 species), Fusarium (3 species), Paecilomyces (2 species), Penicillium (2 species), Rhizopus (1 species), Trichoderma (2 species), isolated from tuberculosis patients with suspected bronchopulmonary and disseminated mycoses in the Moscow Research and Clinical Center of Tuberculosis Control in the period 2012–2024.
Results. Testing revealed high activity of itraconazole against pathogens of candidiasis (except C. glabrata), cryptococcosis, aspergillosis (except A. ustus), pheohyphomycosis (genera Alternaria, Aureobasidium, Cladosporium, Curvularia), rare yeast mycoses (genera Geotasidium, Aureobasidium, Curvularia). ustus), pheohyphomycoses (genera Alternaria, Aureobasidium, Cladosporium, Curvularia), rare yeast mycoses (genera Geotrichum, Hanseniaspora, Saccharomyces, Saprochaete, Trichosporon), hyalohyphomycoses (genera Penicillium, Trichoderma). The activity of itraconazole was low against the pathogens Fusarium spp., Rhodotorulosis (Rhodotorula spp.), Zygomycosis (Rhizopus arrhizus) and variable against two hyalohyphomycetes Paecilomyces variotii and Acremonium strictum.
About the Authors
A. B. Kulko
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
A. I. Isakova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
S. G. Safonova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
References
1. Атлас грибковых заболеваний / Под ред. К.А. Кауфман, Д.Л. Манделла: Пер. с англ. – М.: ГЭОТАР-Медиа. – 2010. – 240 с.
2. Диагностика и лечение микозов / Под ред. Д.Р. Хоспентала, М.Дж. Риналди: Пер. с англ. – М.: ГЭОТАР-Медиа, 2013. – 448 с.
3. Климко Н.Н. Микозы: диагностика и лечение. Руководство для врачей. – 2-е изд., перераб. и доп. – М.: Ви Джи Групп, 2008. – 336 с.
4. Кулько А.Б. Бронхолегочные микозы у больных туберкулезом: состав и свойства возбудителей, лабораторная диагностика: Автореф. дисс. … д-ра биол. наук. – М., 2020. – 49 с.
5. Кулько А.Б. Группы возбудителей оппортунистических пневмомикозов у больных туберкулезом: протокол лабораторного исследования, активность лекарственных препаратов // Туберкулез и социально значимые заболевания. – 2021. – Т. 9 – № 2 (34). – С. 32-37.
6. Кулько А.Б., Древаль П.А., Воробьев А.А., Трусов В.Н. Лабораторная диагностика бронхолегочного аспергиллеза у больных туберкулезом с полостными образованиями в легких // Проблемы медицинской микологии. – 2008. – Т. 10. – № 4. – С. 25-28.
7. Сергеев А.Ю., Сергеев Ю.В. Грибковые инфекции. Руководство для врачей. – М.: Изд-во «Бином», 2008. – 480 с.
8. Agarwal R., Vishwanath G., Aggarwal A.N. et al. Itraconazole in chronic cavitary pulmonary aspergillosis: A randomized controlled trial and systematic review of literature // Mycoses. – 2013. – Vol. 56, № 5. – P. 559-570. doi: 10.1111/myc.12075.
9. Arendrup M.C., Friberg N., Mares M. et al. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST) // Clin. Microbiol. Infect. – 2020. – Vol. 26, № 11. – P. 1464-1472. https://www.sciencedirect.com/journal/clinical-microbiology-and-infection/vol/26/issue/11.
10. Ben-Ami R. Systemic antifungal therapy for invasive pulmonary infections // J. Fungi. – 2023. – Vol. 9 (2), № 144. – P. 1-24. [https://doi.org/10.3390/jof9020144].
11. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts / 3rd informational supplement. CLSI document M27-S3. CLSI. – Wayne, PA., 2008.
12. Cornelia L.-F., Manuel C.-E. Changes in the epidemiological landscape of invasive mould infections and disease // J. Antimicrob. Chemother. – 2017. – Vol. 72, № 1. – P. i5–i11. doi: 10.1093/jac/dkx028.
13. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs for antifungal agents, version 10.0, 2020.
14. Glasmacher A., Prentice A. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy // Clin. Microbiol. Infect. – 2006. – Vol. 12, №7. – P. 84-90. https://www.sciencedirect.com/journal/clinical-microbiology-and-infection/vol/26/issue/.
15. Hoog de G.S., Guarro J., Gene J., Figueras M.J. Atlas of clinical fungi. Electronic Version 3.1 – CBS: Reus, 2011. – URL: http://www.clinicalfungi.org/.
16. Nett J.E., Andes D.R. Antifungal agents: spectrum of activity, pharmacology, and clinical indications // Infect. Dis. Clin. N. Am. – 2016. – Vol. 30, № 1. – P. 51-83. doi: 10.1016/j.idc.2015.10.012.
17. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 // J. Clin. Microbiol. – 2012. – Vol. 50, № 9. – P. 2846-2856.
Review
For citations:
Kulko A.B., Isakova A.I., Safonova S.G. In vitro activity of itraconazole against yeast and mycelial fungi – pathogens of opportunistic mycoses in tuberculosis patients. Tuberculosis and socially significant diseases. 2024;12(4):18-24. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-4-18-24
Views:
124
Email this article 